Back in November 2020, Cassava priced its public offering at $8 per share. Proceeds of $75 million were meant to support the Phase 3 study. Since then, SAVA stock has traded as high as $146, without a ...
Cassava Sciences' Alzheimer's drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials. SAVA stock ...
WASHINGTON, July 27 (Reuters) - The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc (SAVA.O), opens new tab involving whether the biotech company manipulated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback